Novan Inc

Novan — Investor Presentation (March 2021)

24 slides from Novan's investor presentation, Mar 9, 2021

  1. Slide 1: Nitric Oxide-Based Medicine Corporate Presentation

    Nitric Oxide-Based Medicine novan.com NASDAQ: NOVN Corporate Presentation March 9, 2021 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements including, but not limited to, statements related to the potential therapeutic value of our NITRICIL™ platform technology, our pharmaceutical development of nitric oxide-releasing product candidates, our intention to ad

  3. Slide 3: Investment Opportunity

    3 Investment Opportunity Pipeline Priorities Multiple Pipeline Expansion Opportunities Development pipeline with potential to progress advanced programs in acne vulgaris, genital warts and atopic dermatitis SB206: Molluscum Ongoing Phase 3 study with data targeted before the end of Q2 2021 1 SB019:

  4. Slide 4: Priority Development Pipeline

    Priority Development Pipeline 4 Product Candidate Indication Pre-IND Phase 1 Phase 2 Phase 3 Approval Program Highlight DERMATOLOGY SB206 Molluscum Target Reporting Topline Results before the end of Q2 2021 INFECTIOUS DISEASE SB019 Coronavirus First Demonstration of Antiviral Effect of NO Against SA

  5. Slide 5: Nitric Oxide (NO) Novel NO Platform Driving Therapeutic Innovation

    Nitric Oxide (NO) 5 Novel NO Platform Driving Therapeutic Innovation Colasanti, M. et al. S-Nitrosylation of Viral Proteins: Molecular Bases for Antiviral Effect of Nitric Oxide IUBMB Life; 1999 (48) 25-31. Kroen, KD. J Clin Invest. 1993;91(6):2446- 2452.; Karupiah, G; et al. Science. 1993;261(5127)

  6. Slide 6: Tunable Dosing Enables Proprietary Formulations That Target Each Indication

    6 Tunable Dosing Enables Proprietary Formulations That Target Each Indication NITRICIL™ Proprietary Nitric Oxide Based Technology Platform Generates Macromolecular New Chemical Entities (NCEs) Key Characteristics: Tunability: pH-controlled release profiles Targeted: delivery to site of infection or

  7. Slide 7: SB206: Lead Program

    7 SB206: Lead Program Berdazimer 10.3% Ongoing Pivotal Phase 3 Study For Treatment of Molluscum Contagiosum Topical antiviral gel for the treatment of viral skin infections 1. Includes all patients treated with berdazimer, including patients currently participating in the SB206 Phase 3 study, B-SIMP

  8. Slide 8: No FDA-Approved Treatments for Molluscum

    8 No FDA-Approved TreatmentsMolluscum Contagious skin infection caused by the molluscipoxvirus, a double- stranded DNA virus Current treatment options are limited: • Off-label Rx/OTC• Physical procedures ~70% of patients below the age of 10 Average time to resolution 13 Months ~3.4 million prevalenc

  9. Slide 9: Development Pathway Towards Potential Approval

    Development Pathway Towards Potential Approval 9 Potential NDA Filing Targeted No Later Than Q3 2022 B-SIMPLE2 Completed B-SIMPLE4 Topline Results Targeted Q2 2021 B-SIMPLE1 Completed Key findings from immense body of data and external experts guided the design of the B-SIMPLE program 352 Subjects

  10. Slide 10: Promising Phase 3 Efficacy Findings With SB206

    Promising Phase 3 Efficacy Findings With SB206 10 Integrated Analysis Demonstrated Statistically Significant (p=0.038) Complete Clearance Rate (27.9%) vs. Vehicle (20.9%) at Week 12 B-SIMPLE1: 352 Subjects B-SIMPLE2: 355 Subjects 0.0% 4.3% 10.3% 21.6% 0.4% 4.7% 15.3% 25.8% 0% 5% 10% 15% 20% 25% 30%

  11. Slide 11: Percent Change from Baseline Lesion Count

    11 B-SIMPLE1 B-SIMPLE2 -60% -50% -40% -30% -20% -10% 0% 10% Week 2 Week 4 Week 8 Week 12 P e rc e n t C h a n g e f ro m B as e lin e L e si o n C o u n t Vehicle SB206 * * * -60% -50% -40% -30% -20% -10% 0% 10% Week 2 Week 4 Week 8 Week 12 P e rc e n t C h a n g e f ro m B as e lin e L e si o n C o

  12. Slide 12: Compelling Safety Profile in B-SIMPLE1 and B-SIMPLE2

    Compelling Safety Profile in B-SIMPLE1 and B-SIMPLE2 12 Similar safety results between the two studies Adverse events were primarily mild to moderate Only treatment emergent adverse events reported in greater than 5% of patients receiving SB206 were application site pain and application site erythem

  13. Slide 13: B-SIMPLE4 Pivotal Phase 3 Study Design in Molluscum

    Treatment 12 Weeks Follow-up at Week 24 13 B-SIMPLE4 Pivotal Phase 3 Study Design in Molluscum Study Design Based on Learnings from B-SIMPLE1 and B-SIMPLE2: One and two-subject household stratification Inflammation of molluscum lesions added as a stratification factor1 Additional patient and caregiv

  14. Slide 14: SB206 Commercialization Strategy

    SB206 Commercialization Strategy 14 Preparing for Success Evaluating All Strategic Options Novan Commercializes Secure Commercialization Partner Co-Commercialize with Partner

  15. Slide 15: Coronavirus (COVID-19) Program

    15 Coronavirus (COVID-19) Program Potential IND filing targeted in 2021 Engaged Catalent, a global leader in providing integrated services, superior delivery technologies and manufacturing solutions, to develop an intranasal formulation of berdazimer sodium First demonstration of antiviral effect of

  16. Slide 16: Companion Animal Health Program

    Companion Animal Health Program 16 Commenced Exploratory Work to Evaluate NO Application in Adjacent Market Engaged third-party animal health experts to determine technical feasibility and market potential Initial formulation development to assess viability in progress Upon positive proof of concept

  17. Slide 17: Pipeline Expansion Opportunities

    Pipeline Expansion Opportunities 17 Ongoing In-Depth Review for Pipeline Prioritization Planned next Phase of development post potentially positive B-SIMPLE4 study of SB206 and subject to obtaining additional financing or strategic partnering Product Candidates Indication Pre-IND Phase 1 Phase 2 Pha

  18. Slide 18: SB206 Related Intellectual Property Protection

    18 SB206 Related Intellectual Property Protection Issued patents projected to expire between 2026 and 2037, without any patent extensions NITRICIL™ Technology • Patents issued in US, China, Germany, Spain, France, Great Britain, Ireland, Italy, Switzerland Formulation Science Related to Viral Skin I

  19. Slide 19: Financial Profile

    19 Financial Profile Nasdaq: NOVN 1. Out of 200,000,000 total common stock authorized per certificate of incorporation. 2. Based on February 10, 2021 closing price of $1.96. 3. Based on Management’s projections and planned development and operating activities described in the Company’s December 31,

  20. Slide 20: Fully Integrated Team Specifically Designed to Execute Strategy

    20 Fully Integrated Team Specifically Designed to Execute Strategy Tomoko Maeda-Chubachi, MD, Ph.D., MBA SVP, Medical Dermatology John M. Gay, CPA Chief Financial Officer Carri Geer, Ph.D. SVP, Chief Technology Officer Paula Brown Stafford, MPH Chairman and Chief Executive Officer Leveraging Extensi

  21. Slide 21: Seasoned Board of Directors

    Seasoned Board of Directors Leveraging Extensive Expertise Across Multiple Industries and Background Paula Brown Stafford, MPH Chairman and Chief Executive Officer W. Kent Geer Lead Independent Director James L. Bierman Director Robert A. Ingram Director Robert J. Keegan Director John Palmour Direct

  22. Slide 22: Upcoming Targeted Milestones

    22 Upcoming Targeted Milestones 1. Cost of study not currently budgeted. SB206 Molluscum SB019 Coronavirus NVN4100 Companion Animal Corporate  September 2020: First Patient Dosed  September 2020: Commenced Study  February 2021: Completed Enrollment Q2 2021: Topline Results 2022: Potential NDA Fil

  23. Slide 23: Investment Summary

    23 Investment Summary Proprietary Nitric Oxide Platform Fueling Pipeline Growth Topline Results From Pivotal B-SIMPLE4 Phase 3 Study Targeted Before the End of Q2 2021 Potential IND Filing for Coronavirus Program Targeted in 2021 Fully-Integrated Team Specifically Designed to Execute

  24. Slide 24: Investor Relations

    Nitric Oxide-Based Medicine Investor Relations JTC Team 833.475.8247 [email protected] novan.com NASDAQ: NOVN

Novan — Investor Presentation (March 2021) on 6ix